 Carlos Roncal
Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uric Acid | 14 | 2019 | 164 | 1.060 |
Why?
| | Fructose | 13 | 2018 | 112 | 0.980 |
Why?
| | Kidney Diseases | 9 | 2019 | 407 | 0.760 |
Why?
| | Hyperuricemia | 8 | 2019 | 44 | 0.610 |
Why?
| | Metabolic Syndrome | 7 | 2018 | 354 | 0.540 |
Why?
| | Allopurinol | 4 | 2019 | 61 | 0.450 |
Why?
| | Diabetic Nephropathies | 6 | 2019 | 300 | 0.380 |
Why?
| | Kidney | 11 | 2019 | 1466 | 0.350 |
Why?
| | Nephritis, Interstitial | 2 | 2007 | 14 | 0.330 |
Why?
| | Captopril | 1 | 2009 | 12 | 0.320 |
Why?
| | Antimetabolites | 1 | 2009 | 21 | 0.320 |
Why?
| | Uromodulin | 2 | 2019 | 21 | 0.310 |
Why?
| | Rats, Sprague-Dawley | 15 | 2019 | 2463 | 0.300 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 195 | 0.290 |
Why?
| | Rats | 18 | 2019 | 5544 | 0.280 |
Why?
| | Arteriolosclerosis | 1 | 2007 | 1 | 0.280 |
Why?
| | Lead | 1 | 2007 | 64 | 0.260 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2019 | 3661 | 0.220 |
Why?
| | Cisplatin | 1 | 2007 | 320 | 0.220 |
Why?
| | Vascular Stiffness | 2 | 2019 | 494 | 0.210 |
Why?
| | Hypokalemia | 3 | 2008 | 24 | 0.210 |
Why?
| | Glucose | 5 | 2018 | 1029 | 0.200 |
Why?
| | Glomerular Filtration Rate | 5 | 2019 | 743 | 0.200 |
Why?
| | Albuminuria | 3 | 2019 | 186 | 0.200 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 925 | 0.190 |
Why?
| | Acute Kidney Injury | 2 | 2007 | 802 | 0.190 |
Why?
| | Dietary Sucrose | 3 | 2010 | 48 | 0.170 |
Why?
| | Chemokine CCL2 | 4 | 2009 | 116 | 0.160 |
Why?
| | Creatinine | 6 | 2018 | 486 | 0.160 |
Why?
| | Kidney Tubules | 4 | 2008 | 116 | 0.160 |
Why?
| | Glycocalyx | 1 | 2019 | 25 | 0.160 |
Why?
| | Glycopeptides | 1 | 2019 | 43 | 0.150 |
Why?
| | Dehydration | 2 | 2016 | 52 | 0.150 |
Why?
| | Kidney Calculi | 1 | 2018 | 34 | 0.140 |
Why?
| | Animals | 26 | 2019 | 36882 | 0.140 |
Why?
| | Sweetening Agents | 2 | 2009 | 54 | 0.140 |
Why?
| | Heat-Shock Response | 1 | 2018 | 76 | 0.140 |
Why?
| | Dietary Carbohydrates | 2 | 2009 | 155 | 0.140 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 46 | 0.140 |
Why?
| | Hydrochlorothiazide | 2 | 2007 | 9 | 0.140 |
Why?
| | Sugars | 1 | 2018 | 41 | 0.140 |
Why?
| | Diuretics | 2 | 2007 | 70 | 0.130 |
Why?
| | Hypertension, Renal | 2 | 2007 | 16 | 0.130 |
Why?
| | Proteinuria | 5 | 2008 | 97 | 0.130 |
Why?
| | Oxidative Stress | 4 | 2019 | 1318 | 0.130 |
Why?
| | Survival | 1 | 2016 | 38 | 0.130 |
Why?
| | Water Supply | 1 | 2016 | 78 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 2111 | 0.120 |
Why?
| | Metabolic Diseases | 1 | 2016 | 108 | 0.110 |
Why?
| | Male | 23 | 2019 | 67386 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2008 | 545 | 0.110 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 278 | 0.110 |
Why?
| | Farmers | 1 | 2015 | 64 | 0.110 |
Why?
| | Heat Stress Disorders | 1 | 2015 | 76 | 0.110 |
Why?
| | Climate Change | 1 | 2016 | 184 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2018 | 559 | 0.100 |
Why?
| | Macrophages | 4 | 2010 | 1540 | 0.100 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1706 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 971 | 0.100 |
Why?
| | Body Weight | 4 | 2009 | 985 | 0.090 |
Why?
| | Inflammation | 3 | 2008 | 2831 | 0.090 |
Why?
| | Blood Pressure | 6 | 2009 | 1786 | 0.090 |
Why?
| | Liver | 2 | 2018 | 1867 | 0.090 |
Why?
| | Kidney Tubules, Proximal | 2 | 2010 | 132 | 0.090 |
Why?
| | Drug Synergism | 2 | 2009 | 368 | 0.090 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2009 | 139 | 0.090 |
Why?
| | Urate Oxidase | 2 | 2008 | 11 | 0.080 |
Why?
| | Hypertension | 4 | 2008 | 1299 | 0.080 |
Why?
| | Insulin Resistance | 5 | 2009 | 1226 | 0.080 |
Why?
| | Capillaries | 2 | 2007 | 108 | 0.080 |
Why?
| | Disease Models, Animal | 6 | 2009 | 4276 | 0.080 |
Why?
| | Animal Feed | 1 | 2009 | 53 | 0.080 |
Why?
| | Xanthine Oxidase | 1 | 2009 | 81 | 0.080 |
Why?
| | Angiostatins | 1 | 2008 | 3 | 0.080 |
Why?
| | Cells, Cultured | 6 | 2019 | 4136 | 0.070 |
Why?
| | Weight Gain | 2 | 2008 | 535 | 0.070 |
Why?
| | Kidney Glomerulus | 1 | 2008 | 119 | 0.070 |
Why?
| | Chronic Disease | 3 | 2008 | 1774 | 0.070 |
Why?
| | Biomarkers | 4 | 2019 | 4095 | 0.070 |
Why?
| | Fatty Liver | 1 | 2009 | 242 | 0.060 |
Why?
| | Leptin | 1 | 2008 | 242 | 0.060 |
Why?
| | Dietary Fats | 1 | 2008 | 305 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 1022 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 2015 | 0.060 |
Why?
| | Renal Circulation | 1 | 2006 | 65 | 0.060 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 295 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2008 | 508 | 0.060 |
Why?
| | Renal Insufficiency | 1 | 2008 | 160 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 839 | 0.060 |
Why?
| | Nitric Oxide | 5 | 2008 | 883 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 556 | 0.060 |
Why?
| | Gout Suppressants | 2 | 2019 | 19 | 0.060 |
Why?
| | Chemokines | 1 | 2005 | 225 | 0.060 |
Why?
| | Fructokinases | 2 | 2018 | 32 | 0.060 |
Why?
| | Th1 Cells | 1 | 2005 | 141 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2009 | 2553 | 0.050 |
Why?
| | Young Adult | 5 | 2019 | 13218 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 850 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2005 | 299 | 0.050 |
Why?
| | Risk Factors | 4 | 2019 | 10363 | 0.050 |
Why?
| | Energy Metabolism | 1 | 2009 | 919 | 0.050 |
Why?
| | Organ Size | 3 | 2010 | 472 | 0.050 |
Why?
| | Kidney Failure, Chronic | 2 | 2005 | 569 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2008 | 784 | 0.050 |
Why?
| | Rats, Wistar | 2 | 2018 | 448 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2007 | 2788 | 0.050 |
Why?
| | Humans | 18 | 2019 | 136965 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2456 | 0.050 |
Why?
| | Aorta | 2 | 2019 | 415 | 0.050 |
Why?
| | Adolescent | 5 | 2019 | 21471 | 0.050 |
Why?
| | Blotting, Western | 3 | 2008 | 1216 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3556 | 0.040 |
Why?
| | Fibrosis | 3 | 2008 | 542 | 0.040 |
Why?
| | Blood Urea Nitrogen | 2 | 2009 | 53 | 0.040 |
Why?
| | Calcium Oxalate | 1 | 2018 | 6 | 0.040 |
Why?
| | Half-Life | 1 | 2018 | 143 | 0.040 |
Why?
| | Biological Availability | 1 | 2018 | 133 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.040 |
Why?
| | High Fructose Corn Syrup | 1 | 2018 | 8 | 0.040 |
Why?
| | Carbonated Beverages | 1 | 2018 | 16 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 303 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 165 | 0.030 |
Why?
| | Pulse Wave Analysis | 1 | 2019 | 272 | 0.030 |
Why?
| | Lipogenesis | 1 | 2018 | 61 | 0.030 |
Why?
| | Beverages | 1 | 2018 | 68 | 0.030 |
Why?
| | Potassium | 2 | 2008 | 142 | 0.030 |
Why?
| | Diabetic Angiopathies | 1 | 2019 | 260 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 554 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 625 | 0.030 |
Why?
| | Sodium | 2 | 2007 | 199 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 783 | 0.030 |
Why?
| | Female | 6 | 2019 | 73002 | 0.030 |
Why?
| | Cystatin C | 1 | 2015 | 65 | 0.030 |
Why?
| | El Salvador | 1 | 2015 | 6 | 0.030 |
Why?
| | Metformin | 1 | 2019 | 336 | 0.030 |
Why?
| | Eating | 1 | 2018 | 392 | 0.030 |
Why?
| | Models, Biological | 2 | 2015 | 1780 | 0.030 |
Why?
| | Adult | 4 | 2019 | 37715 | 0.030 |
Why?
| | Saccharum | 1 | 2015 | 77 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 522 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2018 | 1073 | 0.030 |
Why?
| | Child | 3 | 2019 | 21760 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 621 | 0.030 |
Why?
| | Insulin | 3 | 2008 | 2394 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 838 | 0.020 |
Why?
| | Mice, Inbred C57BL | 3 | 2009 | 5733 | 0.020 |
Why?
| | Pilot Projects | 1 | 2018 | 1730 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3148 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1999 | 0.020 |
Why?
| | Glucose Transporter Type 5 | 1 | 2010 | 3 | 0.020 |
Why?
| | Glucose Transporter Type 2 | 1 | 2010 | 15 | 0.020 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 698 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2008 | 2999 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 49 | 0.020 |
Why?
| | Hyperplasia | 1 | 2010 | 175 | 0.020 |
Why?
| | Nephritis | 1 | 2009 | 24 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling 3 Protein | 1 | 2008 | 9 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 6786 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 21 | 0.020 |
Why?
| | Disease Progression | 2 | 2007 | 2708 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 2184 | 0.020 |
Why?
| | Starvation | 1 | 2008 | 23 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3258 | 0.020 |
Why?
| | Gout | 1 | 2008 | 36 | 0.020 |
Why?
| | Adenoviridae | 1 | 2008 | 194 | 0.020 |
Why?
| | Potassium, Dietary | 1 | 2007 | 12 | 0.020 |
Why?
| | Aldosterone | 1 | 2007 | 43 | 0.020 |
Why?
| | Hypothalamus | 1 | 2008 | 152 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2008 | 203 | 0.020 |
Why?
| | Actins | 1 | 2010 | 415 | 0.020 |
Why?
| | Urine | 1 | 2007 | 59 | 0.020 |
Why?
| | Hypertrophy | 1 | 2008 | 131 | 0.020 |
Why?
| | Hypertriglyceridemia | 1 | 2007 | 39 | 0.020 |
Why?
| | Collagen | 1 | 2010 | 449 | 0.020 |
Why?
| | Magnesium | 1 | 2007 | 155 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2008 | 396 | 0.020 |
Why?
| | Triglycerides | 1 | 2009 | 525 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2008 | 178 | 0.020 |
Why?
| | Atrophy | 1 | 2007 | 188 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2115 | 0.020 |
Why?
| | Kidney Cortex | 1 | 2006 | 26 | 0.020 |
Why?
| | Random Allocation | 1 | 2007 | 352 | 0.020 |
Why?
| | Fasting | 1 | 2008 | 282 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2008 | 179 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 501 | 0.020 |
Why?
| | Sodium Chloride, Dietary | 1 | 2006 | 36 | 0.020 |
Why?
| | Arterioles | 1 | 2006 | 52 | 0.020 |
Why?
| | Mice | 3 | 2009 | 17705 | 0.020 |
Why?
| | Angiotensin II | 1 | 2006 | 96 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2008 | 481 | 0.010 |
Why?
| | Vasoconstrictor Agents | 1 | 2006 | 128 | 0.010 |
Why?
| | Middle Aged | 2 | 2018 | 33226 | 0.010 |
Why?
| | Kidney Function Tests | 1 | 2005 | 157 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1045 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2005 | 185 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 2005 | 274 | 0.010 |
Why?
| | NADPH Oxidases | 1 | 2005 | 139 | 0.010 |
Why?
| | Fibroblasts | 1 | 2010 | 997 | 0.010 |
Why?
| | Antioxidants | 1 | 2008 | 588 | 0.010 |
Why?
| | Body Composition | 1 | 2008 | 690 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2019 | 10664 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5530 | 0.010 |
Why?
| | NF-kappa B | 1 | 2008 | 676 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1229 | 0.010 |
Why?
| | Vasodilation | 1 | 2007 | 497 | 0.010 |
Why?
| | Evolution, Molecular | 1 | 2008 | 514 | 0.010 |
Why?
| | Reference Values | 1 | 2005 | 797 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2007 | 348 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2855 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1085 | 0.010 |
Why?
| | Cattle | 1 | 2005 | 982 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2809 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1923 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2005 | 1083 | 0.010 |
Why?
| | Aged | 1 | 2018 | 23803 | 0.010 |
Why?
| | RNA | 1 | 2005 | 922 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2070 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1712 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 2574 | 0.010 |
Why?
|
|
Roncal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|